NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Kiniksa Pharmaceuticals International, plc (KNSA) Stock Analysis

Kiniksa Pharmaceuticals International, plc (KNSA) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

KNSA

$77.91

−$2.56 (−3.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KNSA with… →

KNSA Key Statistics

As of Sep 4, 2026
Trading
Open
$79.75
Previous Close
$80.47
Day's Range
77.90–80.43
52-Week Range
35.12–82.94
Volume
429.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.09
Valuation
Market Cap
$6.08B
P/E Ratio
81.16
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
48.17
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.23
EPS (ttm)Profit attributable to each share over the last twelve months.
0.96
Financials (FY)
Revenue (FY)
$677.56M+60.09%
Net Income (FY)
$59.01M
Profit marginThe share of revenue left as profit after all costs and taxes.
9.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.29M
1-Year Return
+119.40%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
732.33K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KNSA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+88.87%
2025+108.54%
2024+12.77%
2023+17.09%
2022+27.27%
2021−33.39%
2020+59.76%
2019−60.63%
2018 (partial year)+44.72%

As of September 4, 2026.

KNSA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$677.56M$59.01M8.7%
2024$423.24M−$43.19M−10.2%
2023$270.26M$14.08M5.2%
2022$220.18M$183.36M83.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$677.56M$370.35M$77.22M$59.01M8.7%
2024$423.24M$362.33M−$45.62M−$43.19M−10.2%
2023$270.26M$236.85M−$25.20M$14.08M5.2%
2022$220.18M$197.29M$9.77M$183.36M83.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KNSA Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricKNSADrug Manufacturers - Specialty & Generic medianvs median
P/E81.1619.274.2x the median
P/S ratio7.232.303.1x the median
Profit margin9.59%−3.14%12.7 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Kiniksa Pharmaceuticals International, plc (KNSA) at $6.08B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 366 employees.

The most recent close on file for KNSA is $77.91, dated September 4, 2026. That is −$2.56 (−3.18%) against the previous close. Over the past 52 weeks the price has ranged from $35.12 to $82.94. The latest close sits 121.84% above that 52-week low.

Financial Health

In fiscal 2025, Kiniksa Pharmaceuticals International, plc reported revenue of $677.56M. That is +60.09% against the prior fiscal year, when revenue was $423.24M. The same year closed with net income of $59.01M. Profit margin runs at 9.59%. That is 12.7 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 0.96.

Across the 4 fiscal years on file, revenue moves from $220.18M in 2022 to $677.56M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 81.16 times earnings. That is 4.2 times the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 48.17. The price-to-sales ratio is 7.23. On price-to-sales that is 3.1 times the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +119.40%. Measured over 5 years, that is +44.61% a year compounded. The reported beta is 0.09. Annualized volatility over the trailing 8 years is 63.71%.

Growth & Income

The record shows no dividend for KNSA.

The strongest complete calendar year on file is 2025 at +108.54%; the weakest is 2019 at −60.63%. Of the 7 complete calendar years on file, 5 finished higher. 2026 is still running; the price is +88.87% year to date.

Peer Comparison

Kiniksa Pharmaceuticals International, plc (KNSA) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kiniksa Pharmaceuticals International, plc KNSA $6.08B 81.2
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Kiniksa Pharmaceuticals International, plc trades at a P/E of 81.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

Visit website →